# Lactoferrin in the treatment of Long COVID

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

### **Summary**

### ID

NL-OMON21473

Source NTR

Brief title LARGO

**Health condition** 

Long COVID

### **Sponsors and support**

**Primary sponsor:** Stichting O&O Franciscus Gasthuis & Vlietland **Source(s) of monetary or material Support:** Bonusan B.V.

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

- Do fatigue symptoms diminish faster with the use of lactoferrin combined with usual care compared to usual care solely?

#### Secondary outcome

1 - Lactoferrin in the treatment of Long COVID 13-05-2025

- Do anxiety and depressive symptoms diminish (faster) with the use of lactoferrin?
- Does the use of lactoferrin (faster) improve cognitive function?
- Does muscle strength recover (faster) with the use of lactoferrin?
- Does the use of lactoferrin have an effect on inflammatory blood parameters?
- How do changes in subjective health parameters correlate with circulating biomarkers?

# **Study description**

#### **Background summary**

Rationale: Lactoferrin is an antimicrobial iron-binding glycoprotein that can modulate the immune system and lower oxidative stress levels. Recent evidence indicates a faster recovery from (acute) COVID-19 after using (bovine) lactoferrin supplements. Yet, the effect of lactoferrin in patients suffering from long COVID has not yet been studied. Since immune dysregulation, higher oxidative stress levels and viral persistence could explain at least part of the Long COVID persisting symptoms, including fatigue, muscle weakness, cognitive dysfunction and anxiety and depression, we want to initiate a clinical- and laboratory study looking into the effects of bovine lactoferrin in these patients.

Main objective: To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.

Study design: Investigator-initiated double-blind randomized controlled trial.

Study population: Long COVID patients aged 18-70 years with confirmed COVID-19 (positive RT-PCR or antibody test not older than 9 months).

Intervention (if applicable): Lactoferrin 4 x 300 mg capsules (total 1200 mg) (Bonusan) versus identical placebo capsules; given daily during 6 weeks.

Main study parameters/endpoints: Primary endpoint: Fatigue symptoms (measured with FAS) within 6 weeks and 3 months after initiation of intervention.

Secondary endpoints: Cognitive function (CFQ), Anxiety and depression (HADS), Inflammatory parameters in blood (e.g. IL-6, hsCRP) and muscle strength (Handgrip strength and 30sec Sitto-Stand test).

#### **Study objective**

To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.

#### Study design

baseline, 6 and 12 weeks

#### Intervention

Lactoferrin 1200 mg/day versus Placebo

2 - Lactoferrin in the treatment of Long COVID 13-05-2025

# Contacts

**Public** Franciscus Gasthuis & Vlietland Gert-Jan Braunstahl

010-4617568 **Scientific** Franciscus Gasthuis & Vlietland Gert-Jan Braunstahl

010-4617568

# **Eligibility criteria**

### **Inclusion criteria**

- Persistent or newly developed long COVID symptoms at least 12 weeks post-primary SARS-CoV-2 infection

- Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9 months
- Adult patients with age >18 years

### **Exclusion criteria**

- Patients admitted to the ICU (COVID-19-related)
- COVID-19-related cardiac or pulmonary tissue damage
- Acute infection or current systemic immunological disorders
- Oral and/or inhaled use of corticosteroids or use of other immune-modulatory medication
- Current psychiatric disorders
- Communication difficulties
- Pregnant or lactating women
- Age >70 years

- Patients with milk allergy or a known or suspected allergy or any contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can be used by individuals with lactose intolerance)

# Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

#### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	16-01-2022
Enrollment:	72
Туре:	Anticipated

### **IPD sharing statement**

Plan to share IPD: Undecided

# **Ethics review**

Positive opinion	
Date:	23-09-2021
Application type:	First submission

# **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

#### Register

NTR-new Other ID NL9742 MEC-U : MEC-U 21.081

# **Study results**